Pfizer and BioNTech win FDA approval for XFG-adapted COMIRNATY

The companies' 2026-2027 mRNA COVID-19 vaccine, targeting the XFG variant, has been approved for high-risk adults and children aged five and over.

The Biotech Times Editorial Team By The Biotech Times Editorial Team
A bright, modern laboratory features a row of five transparent bioreactor vessels containing glowing red spherical structures connected by clear tubing, with a microscope and other scientific equipment on white lab benches.

Pfizer and BioNTech have received US FDA approval for their updated COMIRNATY formulation targeting the XFG SARS-CoV-2 variant, clearing the path for the 2026-2027 COVID-19 vaccination season. The supplemental Biologics Licence Application (sBLA) covers adults aged 65 and older, and individuals aged five through 64 who have at least one underlying condition placing them at high risk of severe disease. Shipping began immediately following the approval announcement on 27 August 2026.

The approval rests on the cumulative body of clinical, non-clinical and real-world evidence already on file for COMIRNATY, supplemented by immunogenicity data showing that the XFG-adapted formulation generated strong immune responses not only against XFG itself but also against several co-circulating lineages including XFG.1.1, NB.1.8.1, PQ.17 and PQ.2.8.1. More than five billion doses of COMIRNATY have been distributed globally to date, a scale that has generated an unusually large pharmacovigilance dataset underpinning the sBLA.

Regulatory context

The XFG composition was selected in line with FDA guidance issued in May 2026, which designated it as the preferred strain for vaccines entering distribution from autumn 2026. This strain-selection mechanism mirrors the annual influenza vaccine update process, reflecting the regulatory framework that has been in place for COVID-19 vaccines since the bivalent era. The FDA's decision to base approval on existing platform safety and efficacy data, supplemented by immunobridging evidence for the new formulation, has become standard practice for adapted COVID-19 vaccines and significantly compresses the approval timeline compared with the original primary authorisation.

Notably, the approved indication is narrower than the universal adult label that characterised earlier COMIRNATY formulations. By targeting those aged 65-plus and high-risk individuals aged five to 64, the approval reflects evolving public health thinking on the risk-benefit calculus for the broader healthy adult population, where updated guidance from advisory bodies such as the CDC's Advisory Committee on Immunisation Practices continues to carry significant commercial weight.

Market landscape

The annual COVID-19 vaccine market has consolidated substantially since its pandemic-era peak. Pfizer and BioNTech's COMIRNATY competes primarily with Moderna's mRNA-1273 lineage, which has also received annual updated formulations, and to a lesser extent with protein-subunit options. Uptake rates for seasonal COVID-19 vaccines in the US have trailed influenza vaccination rates in recent years, a dynamic that continues to temper revenue expectations for both companies relative to 2021-2022 highs.

BioNTech holds the Marketing Authorisation for COMIRNATY across the US, EU, UK and other major markets, while Pfizer manages manufacturing, distribution and commercial operations under the collaboration. Both companies have leveraged the mRNA platform developed for COMIRNATY as the technological foundation for broader oncology and infectious disease pipelines, meaning the ongoing success of the COVID-19 franchise carries strategic as well as financial significance. Analysts will watch closely for CDC vaccination rate data in the coming months as the primary indicator of commercial performance for the 2026-2027 season.

Sector

Topic

Geography